Oncology · Colorectal Cancer
The initiation of a liquid biopsy study by City of Hope represents a significant advancement in non-invasive cancer diagnostics, particularly for colorectal cancer. This could disrupt existing screening methods and necessitate a reevaluation of current diagnostic portfolios within the industry.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/9/2026, 12:34:20 AM
Assessment confidence: 65% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The initiation of a liquid biopsy study by City of Hope represents a significant advancement in non-invasive cancer diagnostics, particularly for colorectal cancer. This could disrupt existing screening methods and necessitate a reevaluation of current diagnostic portfolios within the industry. Regulatory context from MHRA (MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer) supports the near-term read. Assessment grounded in 9 ranked evidence items (4 high-relevance).
Portfolio teams should evaluate the implications of this technology on current diagnostic offerings and consider partnerships or investments in liquid biopsy technologies. The strongest clinical anchor is Liquid Biopsy for Early Detection of Colorectal Cancer Using Circular RNA (ClinicalTrials.gov), sub-indication match (colorectal cancer). In colorectal cancer, 0 regulatory and 1 competitive items passed relevance filtering for colorectal cancer diagnostics.
The most relevant competitive pressure comes from New Orthotopic Model Reveals CD8⁺ T Cell Dysfunction in Colorectal Cancer Immunotherapy (Humanexa Signals) — sub-indication match (colorectal cancer). This innovative approach could position City of Hope at the forefront of non-invasive cancer diagnostics, potentially impacting existing screening methods.
Regulatory risk is concentrated around The development of a new diagnostic assay may require regulatory approval, which could influence timelines and compliance strategies for companies in the oncology space..
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceFDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceOngoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View sourceWithdrawn | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View sourceOncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View sourceLiquid Biopsy for Early Detection of Colorectal Cancer Using Circular RNA
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View sourceA Biomarker Exploration Study for Predicting Localization of Recurrence and Metastasis in Colorectal Cancer (PROBE Study)
ClinicalTrials.govmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View sourceColorectal Cancer Screening Outreach
ClinicalTrials.govmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View sourceNew Orthotopic Model Reveals CD8⁺ T Cell Dysfunction in Colorectal Cancer Immunotherapy
Humanexa Signalsmedium relevance
Sub-indication match (colorectal cancer)
NCI Trials CD19/CD22 CAR T Cells for Refractory B Cell Malignancies in Young Patients
Humanexa Signalslow relevance
Broad oncology match without sub-indication specificity
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View sourceAn orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View sourcePRX5 as a critical driver of colorectal cancer stemness and tumorigenicity.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View sourceColorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View sourceCost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe initiation of a liquid biopsy study by City of Hope represents a significant advancement in non-invasive cancer diagnostics, particularly for colorectal cancer. This could disrupt existing screening methods and necessitate a reevaluation of current diagnostic portfolios within the industry.
If successful, this technology could capture significant market share from traditional screening methods, impacting revenue streams for companies involved in colorectal cancer diagnostics.
The development of a new diagnostic assay may require regulatory approval, which could influence timelines and compliance strategies for companies in the oncology space.
Monitor study progress, results publication, and potential collaborations that may arise from this research.
Track for follow-up milestones; no immediate action required.